YDES · YD Bio Ltd · Insider Trading

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").

Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.